First Horizon Advisors, Inc. Arrowhead Pharmaceuticals, Inc. Transaction History

First Horizon Advisors, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	SELL	$29.63 - $48.31 $3,288 - $5,362	-111 Reduced 14.14%	674 $22,000
Q2 2022 Aug 02, 2022	BUY	$27.79 - $50.61 $21,815 - $39,728	785 New	785 $27,000
Q1 2022 May 10, 2022	SELL	$39.62 - $69.97 $36,133 - $63,812	-912 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$58.38 - $84.96 $47,054 - $68,477	806 Added 760.38%	912 $56,000
Q3 2021 Nov 09, 2021	SELL	$58.38 - $84.96 $50,148 - $72,980	-859 Reduced 89.02%	106 $6,000

Q2 2021 Aug 09, 2021	BUY	$62.15 - $90.32 $870 - $1,264	14 Added 1.47%	965 $79,000
Q1 2021 May 11, 2021	SELL	$61.35 - $90.47 $6,257 - $9,227	-102 Reduced 9.69%	951 $63,000
Q4 2020 Feb 11, 2021	BUY	$43.82 - $85.37 $7,055 - $13,744	161 Added 18.05%	1,053 $80,000
Q4 2018 Feb 11, 2019	BUY	$10.74 - $19.7 $9,580 - $17,572	892 New	892 $11,000

296

88.5M

905K

387K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.71B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on First Horizon Advisors, Inc. with notifications on news.